| MeSH term | MeSH ID | Detail |
|---|---|---|
| Carcinoma | D002277 | 18 associated lipids |
| Carcinoma, Non-Small-Cell Lung | D002289 | 72 associated lipids |
| Carcinoma, Papillary | D002291 | 3 associated lipids |
| Carcinosarcoma | D002296 | 7 associated lipids |
| Cardiovascular Diseases | D002318 | 24 associated lipids |
| Celiac Disease | D002446 | 16 associated lipids |
| Brain Ischemia | D002545 | 89 associated lipids |
| Cherubism | D002636 | 1 associated lipids |
| Chondroblastoma | D002804 | 1 associated lipids |
| Chondrocalcinosis | D002805 | 1 associated lipids |
7-octadecynoic acid
7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.
Cross Reference
There are no associated biomedical information in the current reference collection.
Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.
Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.
Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid
Possible diseases from mapped MeSH terms on references
We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid
All references with 7-octadecynoic acid
Download all related citations| Authors | Title | Published | Journal | PubMed Link |
|---|---|---|---|---|
| Yamashita T et al. | Retardation in bone resorption after bone marrow ablation in klotho mutant mice. | 2000 | Endocrinology | pmid:10614667 |
| Mukohyama H et al. | The inhibitory effects of vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide on osteoclast formation are associated with upregulation of osteoprotegerin and downregulation of RANKL and RANK. | 2000 | Biochem. Biophys. Res. Commun. | pmid:10777696 |
| Atkins GJ et al. | Expression of osteoclast differentiation signals by stromal elements of giant cell tumors. | 2000 | J. Bone Miner. Res. | pmid:10780856 |
| Thompson SW and Tonge D | Bone cancer gain without the pain. | 2000 | Nat. Med. | pmid:10802700 |
| Honore P et al. | Osteoprotegerin blocks bone cancer-induced skeletal destruction, skeletal pain and pain-related neurochemical reorganization of the spinal cord. | 2000 | Nat. Med. | pmid:10802707 |
| Onyia JE et al. | In vivo demonstration that human parathyroid hormone 1-38 inhibits the expression of osteoprotegerin in bone with the kinetics of an immediate early gene. | 2000 | J. Bone Miner. Res. | pmid:10804015 |
| Bateman TA et al. | Osteoprotegerin mitigates tail suspension-induced osteopenia. | 2000 | Bone | pmid:10773583 |
| Malyankar UM et al. | Osteoprotegerin is an alpha vbeta 3-induced, NF-kappa B-dependent survival factor for endothelial cells. | 2000 | J. Biol. Chem. | pmid:10811631 |
| Thirunavukkarasu K et al. | The osteoblast-specific transcription factor Cbfa1 contributes to the expression of osteoprotegerin, a potent inhibitor of osteoclast differentiation and function. | 2000 | J. Biol. Chem. | pmid:10833509 |
| Aubin JE and Bonnelye E | Osteoprotegerin and its ligand: A new paradigm for regulation of osteoclastogenesis and bone resorption. | 2000 | Medscape Womens Health | pmid:10792853 |
| Fata JE et al. | The osteoclast differentiation factor osteoprotegerin-ligand is essential for mammary gland development. | 2000 | Cell | pmid:11051546 |
| Miyamoto N et al. | Spindle-shaped cells derived from giant-cell tumor of bone support differentiation of blood monocytes to osteoclast-like cells. | 2000 | J. Orthop. Res. | pmid:11052502 |
| Kinpara K et al. | Osteoclast differentiation factor in human osteosarcoma cell line. | 2000 | J Immunoassay | pmid:11071251 |
| Kong YY et al. | Osteoprotegerin ligand: a regulator of immune responses and bone physiology. | 2000 | Immunol. Today | pmid:11071528 |
| Kobayashi Y et al. | Force-induced osteoclast apoptosis in vivo is accompanied by elevation in transforming growth factor beta and osteoprotegerin expression. | 2000 | J. Bone Miner. Res. | pmid:11028444 |
| Kaneda T et al. | Endogenous production of TGF-beta is essential for osteoclastogenesis induced by a combination of receptor activator of NF-kappa B ligand and macrophage-colony-stimulating factor. | 2000 | J. Immunol. | pmid:11035059 |
| Miyamoto T et al. | An adherent condition is required for formation of multinuclear osteoclasts in the presence of macrophage colony-stimulating factor and receptor activator of nuclear factor kappa B ligand. | 2000 | Blood | pmid:11110710 |
| Proposed standard nomenclature for new tumor necrosis factor members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature. | 2000 | Bone | pmid:11113385 | |
| Takayanagi H et al. | T-cell-mediated regulation of osteoclastogenesis by signalling cross-talk between RANKL and IFN-gamma. | 2000 | Nature | pmid:11117749 |
| Mancini L et al. | Modulation of the effects of osteoprotegerin (OPG) ligand in a human leukemic cell line by OPG and calcitonin. | 2000 | Biochem. Biophys. Res. Commun. | pmid:11118297 |
| Lee ZH et al. | Activation of c-Jun N-terminal kinase and activator protein 1 by receptor activator of nuclear factor kappaB. | 2000 | Mol. Pharmacol. | pmid:11093794 |
| Kong YY and Penninger JM | Molecular control of bone remodeling and osteoporosis. | 2000 | Exp. Gerontol. | pmid:11121682 |
| Shalhoub V et al. | Characterization of osteoclast precursors in human blood. | 2000 | Br. J. Haematol. | pmid:11122091 |
| Proposed standard nomenclature for new tumor necrosis factor family members involved in the regulation of bone resorption. The American Society for Bone and Mineral Research President's Committee on Nomenclature. | 2000 | J. Bone Miner. Res. | pmid:11127193 | |
| Sakuma Y et al. | Impaired bone resorption by lipopolysaccharide in vivo in mice deficient in the prostaglandin E receptor EP4 subtype. | 2000 | Infect. Immun. | pmid:11083800 |
| Riggs BL | The mechanisms of estrogen regulation of bone resorption. | 2000 | J. Clin. Invest. | pmid:11086020 |
| Udagawa N et al. | Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function. | 2000 | Endocrinology | pmid:10965921 |
| Yasuda H | [A new paradigm of osteoclast biology: discovery of OCIF and ODF]. | 2000 | Seikagaku | pmid:10967683 |
| Teitelbaum SL | Bone resorption by osteoclasts. | 2000 | Science | pmid:10968780 |
| Lacey DL et al. | Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo. | 2000 | Am. J. Pathol. | pmid:10934148 |
| Min H et al. | Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis. | 2000 | J. Exp. Med. | pmid:10952716 |
| Shiba H et al. | Effects of ageing on proliferative ability, and the expressions of secreted protein, acidic and rich in cysteine (SPARC) and osteoprotegerin (osteoclastogenesis inhibitory factor) in cultures of human periodontal ligament cells. | 2000 | Mech. Ageing Dev. | pmid:10958924 |
| López FJ | New approaches to the treatment of osteoporosis. | 2000 | Curr Opin Chem Biol | pmid:10959765 |
| Nakashima T et al. | Protein expression and functional difference of membrane-bound and soluble receptor activator of NF-kappaB ligand: modulation of the expression by osteotropic factors and cytokines. | 2000 | Biochem. Biophys. Res. Commun. | pmid:10973797 |
| Itoh K et al. | Importance of membrane- or matrix-associated forms of M-CSF and RANKL/ODF in osteoclastogenesis supported by SaOS-4/3 cells expressing recombinant PTH/PTHrP receptors. | 2000 | J. Bone Miner. Res. | pmid:10976996 |
| Schinke T and Karsenty G | Vascular calcification--a passive process in need of inhibitors. | 2000 | Nephrol. Dial. Transplant. | pmid:10978374 |
| Lorenzo J | Interactions between immune and bone cells: new insights with many remaining questions. | 2000 | J. Clin. Invest. | pmid:10995785 |
| Teng YT et al. | Functional human T-cell immunity and osteoprotegerin ligand control alveolar bone destruction in periodontal infection. | 2000 | J. Clin. Invest. | pmid:10995794 |
| Børset M et al. | Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins. | 2000 | Blood | pmid:11001907 |
| Hofbauer LC and Heufelder AE | Clinical review 114: hot topic. The role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in the pathogenesis and treatment of metabolic bone diseases. | 2000 | J. Clin. Endocrinol. Metab. | pmid:10902778 |
| Rani CS and MacDougall M | Dental cells express factors that regulate bone resorption. | 2000 | Mol. Cell Biol. Res. Commun. | pmid:10860862 |
| Tsurukai T et al. | Roles of macrophage-colony stimulating factor and osteoclast differentiation factor in osteoclastogenesis. | 2000 | J. Bone Miner. Metab. | pmid:10874596 |
| Günther T and Schinke T | Mouse genetics have uncovered new paradigms in bone biology. | 2000 | Trends Endocrinol. Metab. | pmid:10856921 |
| Huang L et al. | Gene expression of osteoprotegerin ligand, osteoprotegerin, and receptor activator of NF-kappaB in giant cell tumor of bone: possible involvement in tumor cell-induced osteoclast-like cell formation. | 2000 | Am. J. Pathol. | pmid:10702390 |
| Capparelli C et al. | Osteoprotegerin prevents and reverses hypercalcemia in a murine model of humoral hypercalcemia of malignancy. | 2000 | Cancer Res. | pmid:10706080 |
| Makhluf HA et al. | Age-related decline in osteoprotegerin expression by human bone marrow cells cultured in three-dimensional collagen sponges. | 2000 | Biochem. Biophys. Res. Commun. | pmid:10679262 |
| Merewether LA et al. | Development of disulfide peptide mapping and determination of disulfide structure of recombinant human osteoprotegerin chimera produced in Escherichia coli. | 2000 | Arch. Biochem. Biophys. | pmid:10683254 |
| Ross FP | RANKing the importance of measles virus in Paget's disease. | 2000 | J. Clin. Invest. | pmid:10712423 |
| Tricot G | New insights into role of microenvironment in multiple myeloma. | 2000 | Lancet | pmid:10675068 |
| Takayanagi H et al. | Involvement of receptor activator of nuclear factor kappaB ligand/osteoclast differentiation factor in osteoclastogenesis from synoviocytes in rheumatoid arthritis. | 2000 | Arthritis Rheum. | pmid:10693864 |
| Itonaga I et al. | Effect of osteoprotegerin and osteoprotegerin ligand on osteoclast formation by arthroplasty membrane derived macrophages. | 2000 | Ann. Rheum. Dis. | pmid:10627423 |
| Chikatsu N et al. | Interactions between cancer and bone marrow cells induce osteoclast differentiation factor expression and osteoclast-like cell formation in vitro. | 2000 | Biochem. Biophys. Res. Commun. | pmid:10631114 |
| Takami M et al. | Intracellular calcium and protein kinase C mediate expression of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in osteoblasts. | 2000 | Endocrinology | pmid:11108286 |
| Gori F et al. | The expression of osteoprotegerin and RANK ligand and the support of osteoclast formation by stromal-osteoblast lineage cells is developmentally regulated. | 2000 | Endocrinology | pmid:11108292 |
| Clohisy DR et al. | Osteoprotegerin inhibits tumor-induced osteoclastogenesis and bone tumor growth in osteopetrotic mice. | 2000 | J. Orthop. Res. | pmid:11192258 |
| Aubin JE and Bonnelye E | Osteoprotegerin and its ligand: a new paradigm for regulation of osteoclastogenesis and bone resorption. | 2000 | Osteoporos Int | pmid:11193242 |
| Wise GE et al. | Osteoprotegerin and osteoclast differentiation factor in tooth eruption. | 2000 | J. Dent. Res. | pmid:11201042 |
| Kotake S et al. | [Molecular mechanism of bone metabolism]. | 2000 | Nippon Naika Gakkai Zasshi | pmid:11215116 |
| Kanematsu M et al. | [Clinostat rotation culture modulates gene expression of osteoclastogenesis-regulating factors via a cyclic-AMP dependent mechanism]. | 2000 | Biol. Sci. Space | pmid:12561872 |
| Goltzman D | Osteolysis and cancer. | 2001 | J. Clin. Invest. | pmid:11375409 |
| Zhang J et al. | Osteoprotegerin inhibits prostate cancer-induced osteoclastogenesis and prevents prostate tumor growth in the bone. | 2001 | J. Clin. Invest. | pmid:11375413 |
| Kostenuik PJ and Shalhoub V | Osteoprotegerin: a physiological and pharmacological inhibitor of bone resorption. | 2001 | Curr. Pharm. Des. | pmid:11375772 |
| Thirunavukkarasu K et al. | Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. | 2001 | J. Biol. Chem. | pmid:11451955 |
| Yun TJ et al. | Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function. | 2001 | J. Immunol. | pmid:11160187 |
| Lories RJ and Luyten FP | Osteoprotegerin and osteoprotegerin-ligand balance: a new paradigm in bone metabolism providing new therapeutic targets. | 2001 | Clin. Rheumatol. | pmid:11254237 |
| Wan M et al. | Transcriptional mechanisms of bone morphogenetic protein-induced osteoprotegrin gene expression. | 2001 | J. Biol. Chem. | pmid:11139569 |
| Browner WS et al. | Associations of serum osteoprotegerin levels with diabetes, stroke, bone density, fractures, and mortality in elderly women. | 2001 | J. Clin. Endocrinol. Metab. | pmid:11158021 |
| Hofbauer LC and Heufelder AE | [Osteoprotegerin ligand and osteoprotegerin: new concepts of the pathogenesis and therapy of metabolic bone diseases]. | 2001 | Dtsch. Med. Wochenschr. | pmid:11233883 |
| Bolon B et al. | Adenoviral delivery of osteoprotegerin ameliorates bone resorption in a mouse ovariectomy model of osteoporosis. | 2001 | Mol. Ther. | pmid:11237676 |
| Sasaki N et al. | Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis. | 2001 | Nephrol. Dial. Transplant. | pmid:11239019 |
| Takeuchi T et al. | Adrenergic stimulation of osteoclastogenesis mediated by expression of osteoclast differentiation factor in MC3T3-E1 osteoblast-like cells. | 2001 | Biochem. Pharmacol. | pmid:11239501 |
| Mori K et al. | Cross-talk between RANKL and FRP-1/CD98 Systems: RANKL-mediated osteoclastogenesis is suppressed by an inhibitory anti-CD98 heavy chain mAb and CD98-mediated osteoclastogenesis is suppressed by osteoclastogenesis inhibitory factor. | 2001 | Cell. Immunol. | pmid:11243701 |
| Hofbauer LC et al. | Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells. | 2001 | Biochem. Biophys. Res. Commun. | pmid:11162519 |
| Brändström H et al. | Regulation of osteoprotegerin secretion from primary cultures of human bone marrow stromal cells. | 2001 | Biochem. Biophys. Res. Commun. | pmid:11162596 |
| Wuyts W et al. | Evaluation of the role of RANK and OPG genes in Paget's disease of bone. | 2001 | Bone | pmid:11165949 |
| Michigami T et al. | Receptor activator of nuclear factor kappaB ligand (RANKL) is a key molecule of osteoclast formation for bone metastasis in a newly developed model of human neuroblastoma. | 2001 | Cancer Res. | pmid:11245477 |
| Feuerherm AJ et al. | Elevated levels of osteoprotegerin (OPG) and hepatocyte growth factor (HGF) in rheumatoid arthritis. | 2001 | Scand. J. Rheumatol. | pmid:11578019 |
| Sakai E et al. | Characterization of phagosomal subpopulations along endocytic routes in osteoclasts and macrophages. | 2001 | J. Biochem. | pmid:11726283 |
| Quinn JM et al. | Transforming growth factor beta affects osteoclast differentiation via direct and indirect actions. | 2001 | J. Bone Miner. Res. | pmid:11585342 |
| Choi SJ et al. | Osteoclast inhibitory peptide 2 inhibits osteoclast formation via its C-terminal fragment. | 2001 | J. Bone Miner. Res. | pmid:11585344 |
| Miyamoto T et al. | Bifurcation of osteoclasts and dendritic cells from common progenitors. | 2001 | Blood | pmid:11588053 |
| Pearse RN et al. | Multiple myeloma disrupts the TRANCE/ osteoprotegerin cytokine axis to trigger bone destruction and promote tumor progression. | 2001 | Proc. Natl. Acad. Sci. U.S.A. | pmid:11562486 |
| Kostenuik PJ et al. | OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats. | 2001 | Endocrinology | pmid:11564687 |
| Marco-Mingot M et al. | Lack of mutations in the RANK gene in Spanish patients with Paget disease of bone. | 2001 | Clin. Genet. | pmid:11531977 |
| Raffai RL et al. | Introduction of human apolipoprotein E4 "domain interaction" into mouse apolipoprotein E. | 2001 | Proc. Natl. Acad. Sci. U.S.A. | pmid:11553788 |
| Hocking LJ et al. | Genomewide search in familial Paget disease of bone shows evidence of genetic heterogeneity with candidate loci on chromosomes 2q36, 10p13, and 5q35. | 2001 | Am. J. Hum. Genet. | pmid:11555792 |
| Hofbauer LC et al. | Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases. | 2001 | Cancer | pmid:11505389 |
| Hofbauer LC and Heufelder AE | Role of receptor activator of nuclear factor-kappaB ligand and osteoprotegerin in bone cell biology. | 2001 | J. Mol. Med. | pmid:11485016 |
| Wise GE et al. | Effects of dexamethasone on tooth eruption in rats: differences in incisor and molar eruption. | 2001 | Clin Anat | pmid:11301468 |
| Atkins GJ et al. | Osteoprotegerin inhibits osteoclast formation and bone resorbing activity in giant cell tumors of bone. | 2001 | Bone | pmid:11336917 |
| Komine M et al. | Tumor necrosis factor-alpha cooperates with receptor activator of nuclear factor kappaB ligand in generation of osteoclasts in stromal cell-depleted rat bone marrow cell culture. | 2001 | Bone | pmid:11344046 |
| Chen D et al. | ELISA methodology for detection of modified osteoprotegerin in clinical studies. | 2001 | Clin. Chem. | pmid:11274028 |
| Collin-Osdoby P et al. | Receptor activator of NF-kappa B and osteoprotegerin expression by human microvascular endothelial cells, regulation by inflammatory cytokines, and role in human osteoclastogenesis. | 2001 | J. Biol. Chem. | pmid:11274143 |
| Brown JM et al. | Osteoprotegerin and rank ligand expression in prostate cancer. | 2001 | Urology | pmid:11306358 |
| Fukagawa M et al. | [PTH and bone metabolism in chronic dialysis patients]. | 2001 | Rinsho Byori | pmid:11307321 |
| Horowitz MC et al. | Control of osteoclastogenesis and bone resorption by members of the TNF family of receptors and ligands. | 2001 | Cytokine Growth Factor Rev. | pmid:11312114 |
| Lin DL et al. | Bone metastatic LNCaP-derivative C4-2B prostate cancer cell line mineralizes in vitro. | 2001 | Prostate | pmid:11351351 |
| Sparks AB et al. | Mutation screening of the TNFRSF11A gene encoding receptor activator of NF kappa B (RANK) in familial and sporadic Paget's disease of bone and osteosarcoma. | 2001 | Calcif. Tissue Int. | pmid:11351498 |
| Disthabanchong S and González EA | Regulation of bone cell development and function: implication for renal osteodystrophy. | 2001 | J. Investig. Med. | pmid:11352181 |
| Kotake S et al. | Activated human T cells directly induce osteoclastogenesis from human monocytes: possible role of T cells in bone destruction in rheumatoid arthritis patients. | 2001 | Arthritis Rheum. | pmid:11352231 |